Shared and distinct clinical features of patients with inborn errors of the alternative NF-κB pathway
| . | AD NF-κB2 haploinsufficiency (p52LOF/IκBδLOF) . | AD p52-GOF (p52GOF/IκBδLOF) . | AD IκBδ-GOF (p52LOF/IκBδGOF) . | AR NIK deficiency . | AR IKK-α deficiency . | AR RelB deficiency . | AD TRAF3 haploinsufficiency . | AR BAFFR deficiency . | AR LTBR deficiency . | XL-CD40L or AR CD40 deficiency . | AR RANK or RANKL deficiency . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | NFKB2 | NFKB2 | NFKB2 | NIK | CHUK | RELB | TRAF3 | BAFFR | LTBR | CD40/CD40L | RANK/RANKL | |
| IEI/disease group | PAD | PAD | PAD | CID | CID | CID | Immune dysregulation | PAD | CID | CID | Osteopetrosis | |
| Immunological phenotypes | B cells | ↓ Ig, ↓ B cells, and ↑ mem B cells | ↓ Ig and ↓ B cells | ↓↓↓ Ig and ↓↓↓ B cells | ↓↓↓ Ig and ↓↓↓ B cells | ↓↓ Ig and ↓↓ B cells | ↓↓ Ig and ↓↓ B cells | ↑↑ Ig, ↑↑ B cells, and ↓↓ mem B cells | ↓↓↓ Ig and ↓↓↓ B cells | ↓↓↓ Ig and ↓↓↓ mem B cells | ↑↑ IgM, ↓↓↓ IgG, and ↓↓↓ mem B cells | ↓ Ig and ↓ mem B cells |
| T cells | Normal | Normal | ↑ CD4+ naïve T, ↓ cTFh, and ↓ Treg | ↑/↓ CD4+ naïve T and ↓ cTFh | ↑ CD4+ naïve T, ↓ cTFh, and ↓ Treg | ↓ CD4+ naïve T | ↓ CD4+ naïve T, ↑ cTFh, and ↑ Treg | Normal | ↓ cTFh and ↓ Treg | ↓ cTFh | Normal | |
| Susceptibility to infection | Respiratory tract bacterial infections | ++ | ++ | +++ | +++ | ++ | ++ | +++ | ++ | +++ | +++ | ± |
| SARS-CoV-2, influenza, VZV, HSV-1 | - | - | +++ | ++ | +++ | ++ | - | - | - | - | - | |
| Candidiasis (CMC) | - | - | - | +++ | ++ | ++ | - | - | - | - | - | |
| Mycobacterial | - | - | - | ++ | - | - | - | - | - | - | - | |
| Cryptococcal | - | - | - | ++ | - | + | - | - | - | ++ | - | |
| Syndromic features | Pituitary defects | - | - | ++ | - | - | - | - | - | - | - | - |
| Alopecia areata/totalis | - | - | ++ | - | ++ | - | - | - | - | - | - | |
| Nail dystrophy | - | - | ++ | - | ++ | - | - | - | - | - | - | |
| Ectodermal dysplasia (sparse hair, eyebrows, or eyelashes) | - | - | + | - | ++ | - | - | - | - | - | - | |
| SLO development | Lymph nodes | Normal | Lymphadenopathy | Normal | Hypoplasia | Hypoplasia | Hypoplasia | Lymphadenopathy | Normal | Hypoplasia | Normal/hypoplasia | Hypoplasia |
| Spleen | Normal | Normal | Normal | Normal | Normal | Normal | Splenomegaly | Normal | Functional asplenia | Normal | Normal | |
| Autoimmunity | Organ-mediated autoimmunity | ++ | + | ++ | - | ++ | ++ | ++ | - | - | - | - |
| Auto-Abs against type I IFNs | Negative | Negative | Positive | Positive | Positive | Positive | Negative | Negative | Negative | Negative | Negative | |
| . | AD NF-κB2 haploinsufficiency (p52LOF/IκBδLOF) . | AD p52-GOF (p52GOF/IκBδLOF) . | AD IκBδ-GOF (p52LOF/IκBδGOF) . | AR NIK deficiency . | AR IKK-α deficiency . | AR RelB deficiency . | AD TRAF3 haploinsufficiency . | AR BAFFR deficiency . | AR LTBR deficiency . | XL-CD40L or AR CD40 deficiency . | AR RANK or RANKL deficiency . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | NFKB2 | NFKB2 | NFKB2 | NIK | CHUK | RELB | TRAF3 | BAFFR | LTBR | CD40/CD40L | RANK/RANKL | |
| IEI/disease group | PAD | PAD | PAD | CID | CID | CID | Immune dysregulation | PAD | CID | CID | Osteopetrosis | |
| Immunological phenotypes | B cells | ↓ Ig, ↓ B cells, and ↑ mem B cells | ↓ Ig and ↓ B cells | ↓↓↓ Ig and ↓↓↓ B cells | ↓↓↓ Ig and ↓↓↓ B cells | ↓↓ Ig and ↓↓ B cells | ↓↓ Ig and ↓↓ B cells | ↑↑ Ig, ↑↑ B cells, and ↓↓ mem B cells | ↓↓↓ Ig and ↓↓↓ B cells | ↓↓↓ Ig and ↓↓↓ mem B cells | ↑↑ IgM, ↓↓↓ IgG, and ↓↓↓ mem B cells | ↓ Ig and ↓ mem B cells |
| T cells | Normal | Normal | ↑ CD4+ naïve T, ↓ cTFh, and ↓ Treg | ↑/↓ CD4+ naïve T and ↓ cTFh | ↑ CD4+ naïve T, ↓ cTFh, and ↓ Treg | ↓ CD4+ naïve T | ↓ CD4+ naïve T, ↑ cTFh, and ↑ Treg | Normal | ↓ cTFh and ↓ Treg | ↓ cTFh | Normal | |
| Susceptibility to infection | Respiratory tract bacterial infections | ++ | ++ | +++ | +++ | ++ | ++ | +++ | ++ | +++ | +++ | ± |
| SARS-CoV-2, influenza, VZV, HSV-1 | - | - | +++ | ++ | +++ | ++ | - | - | - | - | - | |
| Candidiasis (CMC) | - | - | - | +++ | ++ | ++ | - | - | - | - | - | |
| Mycobacterial | - | - | - | ++ | - | - | - | - | - | - | - | |
| Cryptococcal | - | - | - | ++ | - | + | - | - | - | ++ | - | |
| Syndromic features | Pituitary defects | - | - | ++ | - | - | - | - | - | - | - | - |
| Alopecia areata/totalis | - | - | ++ | - | ++ | - | - | - | - | - | - | |
| Nail dystrophy | - | - | ++ | - | ++ | - | - | - | - | - | - | |
| Ectodermal dysplasia (sparse hair, eyebrows, or eyelashes) | - | - | + | - | ++ | - | - | - | - | - | - | |
| SLO development | Lymph nodes | Normal | Lymphadenopathy | Normal | Hypoplasia | Hypoplasia | Hypoplasia | Lymphadenopathy | Normal | Hypoplasia | Normal/hypoplasia | Hypoplasia |
| Spleen | Normal | Normal | Normal | Normal | Normal | Normal | Splenomegaly | Normal | Functional asplenia | Normal | Normal | |
| Autoimmunity | Organ-mediated autoimmunity | ++ | + | ++ | - | ++ | ++ | ++ | - | - | - | - |
| Auto-Abs against type I IFNs | Negative | Negative | Positive | Positive | Positive | Positive | Negative | Negative | Negative | Negative | Negative | |
+, occasional; ++, commonly observed; +++, very frequent; CID, combined immunodeficiency; CMC, chronic mucocutaneous candidiasis; cTFh, circulating T follicular helper; mem, memory; PAD, predominantly antibody deficiency; SLOs, secondary lymphoid organs.